In terms of cost/efficacy for public healthcare – yes. Not easy to justify expedited approvals.
But resistance to it is lower and it’s believed to have less side effects. Moreover, it sometimes allows retreatment.
However, for general population – BMS’s dac was the first one to come. No doubt why there were no Phase III trials of sof/dac.
It’s good we have several great drugs available.
Gen 1b
VL pre treatment 29000 ME/ml
AST 32 ALT 94, F0
Started treatment 13 January 2017
Generic sofosbuvir/velpatasvir (Incepta)
VL 9 days into treatment <300 (undetected)
AST 13.8 ALT 22
Side effects: mild dehydration, not a problem at all if I drink water at night, nothing to worry about
Diet and gastric ph are very important with velpatasvir. One must think what and when to eat to keep gastric pH low. Side effects disappeared 2 weeks after, unless I ate anything < 4hrs before the pill. SVR60.
.
